Website is still under construction. Call us for any questions.

Spravato FAQs

What is Spravato®?

Spravato® (esketamine) is a prescription nasal spray approved by the FDA for adults with treatment-resistant depression or depressive symptoms in adults with major depressive disorder (MDD) and suicidal thoughts or actions.

Spravato® works on the brain’s glutamate system, unlike traditional antidepressants that target serotonin, norepinephrine, or dopamine. This different mechanism can lead to faster symptom relief for some patients.

You’ll self-administer the nasal spray under medical supervision in our office. Each session typically lasts about two hours, including a monitoring period where we ensure you’re safe and comfortable before going home.

Spravato® treatment begins with twice-weekly sessions for the first four weeks, followed by a gradual tapering schedule based on your individual response and your provider’s recommendations.

No. You must arrange for a trusted friend or family member to drive you home after each session. Spravato® can cause sedation or dizziness, so driving is not safe afterward.

Many insurance plans do cover Spravato®, but coverage can vary. Our team will help guide you through the approval process and work with your insurance provider to determine your benefits.

Some people notice improvement within hours or days, but individual results vary. A full treatment course provides the best chance for lasting relief.